Traws Pharma (TRAW) vs Exicure (XCUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Traws Pharma is the larger company by market cap ($6.8 million vs $6.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRAW | XCUR |
|---|---|---|
| Share price | $0.4452 | $1.02 |
| Market cap | $6.84M | $6.68M |
| 1-day change | -7.31% | +0.99% |
| EPS (TTM) | $-1.71 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.27 | $9.48 |
| 52-week low | $0.43 | $0.936 |
| Distance from 52-week high | -86.39% | -89.24% |
| Analyst consensus | none | — |
| Avg. price target upside | +124.62% | — |
| Average volume | 569.02K | 393.66K |
| Shares outstanding | 15.37M | 6.55M |
| Employees | 4 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Exicure
XCUR stock →Exicure, Inc. does not have significant operations.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
TRAW vs XCUR FAQ
Which is bigger, Traws Pharma or Exicure?
Traws Pharma (TRAW) is larger, with a market capitalization of $6.84M compared with $6.68M for Exicure (XCUR).
Are Traws Pharma and Exicure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.